CLIN CHEM LAB MED:肝素和柠檬酸盐添加剂在采血过程中残留

2020-01-31 MedSci MedSci原创

关于静脉切开术中的附加残留风险的公开证据仍不清楚说明肝素和柠檬酸盐添加剂的影响。我们的目的是评估柠檬酸和肝素化血液的潜在影响,以及临床化学和凝血试验所需的相对体积。<span lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:14.0pt;font-family:"Calibri",sans-serif; mso-

关于静脉切开术中的附加残留风险的公开证据仍不清楚说明肝素和柠檬酸盐添加剂的影响。我们的目的是评估柠檬酸和肝素化血液的潜在影响,以及临床化学和凝血试验所需的相对体积。

我们使用钠和锂作为替代品,模拟了标准化的静脉切开术,以量化蒸馏水中柠檬酸盐和肝素添加剂残留的风险。 我们还研究了随着柠檬酸血液和纯柠檬酸盐体积的增加对肝素化血液样本的污染对钠,钾,氯,镁,总钙和离子钙和磷酸盐的测量的影响。 同样,我们研究了随着肝素化血液量的增加而对柠檬酸血样的污染对肝素(抗Xa)活性,锂,活化的部分凝血活酶时间(APTT),凝血酶原时间(PT)和凝血酶时间(TT)的影响。 我们根据超出分析,生物学和临床意义的测量偏差解释了这些结果。

标准化静脉切开术模拟显示替代标记物浓度无显著差异。肝素化血样污染后,在柠檬酸盐血样中离子化钙的血量超过5-50μL,钠,氯化物和总钙的血量超过100-1000μL,观察到临床上的重大变化。 对纯柠檬酸盐残留物的研究表明,在稍低的体积下,结果相似。 肝素化血液残留量超过5–100μL时,显示临床上明显的凝血测试干扰。

结果表明,在标准化的静脉切开术中,肝素或柠檬酸污染是非常不可能的。然而,较小的体积足以严重违反静脉切开术指导原则而改变测试结果。

原始出处:

Martin H. KeppelSimon AuerHeparin and citrate additive carryover during blood collection

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1362055, encodeId=b40713620558d, content=<a href='/topic/show?id=b3d195659ce' target=_blank style='color:#2F92EE;'>#采血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95659, encryptionId=b3d195659ce, topicName=采血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sun Feb 02 14:53:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542158, encodeId=20ae1542158a2, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Sun Feb 02 14:53:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610209, encodeId=d5df1610209ec, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Feb 02 14:53:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613785, encodeId=8fd91613e8502, content=<a href='/topic/show?id=b34d662091f' target=_blank style='color:#2F92EE;'>#添加剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66209, encryptionId=b34d662091f, topicName=添加剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9e19427308, createdName=ms6832696159214430, createdTime=Sun Feb 02 14:53:00 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1362055, encodeId=b40713620558d, content=<a href='/topic/show?id=b3d195659ce' target=_blank style='color:#2F92EE;'>#采血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95659, encryptionId=b3d195659ce, topicName=采血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sun Feb 02 14:53:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542158, encodeId=20ae1542158a2, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Sun Feb 02 14:53:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610209, encodeId=d5df1610209ec, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Feb 02 14:53:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613785, encodeId=8fd91613e8502, content=<a href='/topic/show?id=b34d662091f' target=_blank style='color:#2F92EE;'>#添加剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66209, encryptionId=b34d662091f, topicName=添加剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9e19427308, createdName=ms6832696159214430, createdTime=Sun Feb 02 14:53:00 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1362055, encodeId=b40713620558d, content=<a href='/topic/show?id=b3d195659ce' target=_blank style='color:#2F92EE;'>#采血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95659, encryptionId=b3d195659ce, topicName=采血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sun Feb 02 14:53:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542158, encodeId=20ae1542158a2, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Sun Feb 02 14:53:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610209, encodeId=d5df1610209ec, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Feb 02 14:53:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613785, encodeId=8fd91613e8502, content=<a href='/topic/show?id=b34d662091f' target=_blank style='color:#2F92EE;'>#添加剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66209, encryptionId=b34d662091f, topicName=添加剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9e19427308, createdName=ms6832696159214430, createdTime=Sun Feb 02 14:53:00 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1362055, encodeId=b40713620558d, content=<a href='/topic/show?id=b3d195659ce' target=_blank style='color:#2F92EE;'>#采血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95659, encryptionId=b3d195659ce, topicName=采血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sun Feb 02 14:53:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542158, encodeId=20ae1542158a2, content=<a href='/topic/show?id=669d6185e3e' target=_blank style='color:#2F92EE;'>#柠檬酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61857, encryptionId=669d6185e3e, topicName=柠檬酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=725913361726, createdName=ms5236388012055669, createdTime=Sun Feb 02 14:53:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610209, encodeId=d5df1610209ec, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Feb 02 14:53:00 CST 2020, time=2020-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613785, encodeId=8fd91613e8502, content=<a href='/topic/show?id=b34d662091f' target=_blank style='color:#2F92EE;'>#添加剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66209, encryptionId=b34d662091f, topicName=添加剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d9e19427308, createdName=ms6832696159214430, createdTime=Sun Feb 02 14:53:00 CST 2020, time=2020-02-02, status=1, ipAttribution=)]

相关资讯

JACC Cardiovasc Inte:冠状动脉造影时,用高剂量肝素可预防桡动脉闭塞

桡动脉闭塞无症状,是经桡动脉冠状动脉造影后一种常见并发症。

患者血小板下降,居然还要抗凝?

患者54岁男性,主因“间断心前区疼痛1月”入院。入院前1月多于劳累后或活动量增加后出现心前区疼痛,伴出汗及左上肢放射痛,休息后约10分钟症状可缓解,未正规诊治。

Blood:多反应性IgM通过PF4/肝素复合物激活经典信号通路启动补体激活

中心点:多反应性IgM通过PF4/肝素复合物激活经典信号通路介导补体活化。在健康供者中,PF4/肝素复合物的补体激活存在很大差异。摘要:多种(如果不是大部分)受体暴露于肝素所引发的抗体反应的机制尚不明确。Sanjay Khandelwal等人近期发现抗原血小板因子4(PF4)/肝素复合物可激活血浆中的补体,并与B细胞结合,其对该过程是如何起始进行了深入研究。当研究人员将PF4/肝素复合物加入健康供

人工股骨头置换术后肝素诱发血小板减少症1例

肝素是预防和治疗血栓性疾病常用药物之一,而血小板减少症是其容易漏诊、误诊、发病隐匿而且极为罕见的并发症,即肝素诱发血小板减少症(HIT)。HIT的特点是血小板减少,伴或不伴有动静脉血栓形成,其致残率和死亡率很高,在临床医师应有足够的认识和重视。笔者回顾性分析于2018-02-20诊治的1例人工股骨头置换术后HIT患者临床资料,并对相关文献进行复习总结,报道如下。

AHJ:STEMI患者直接PCI抗凝:比伐卢定PK肝素

ST段抬高心肌梗死(STEMI)患者直接PCI抗凝治疗应选择肝素还是比伐卢定?2018年7月,发表在《American Heart Journal》的一项研究对此进行分析。

JAMA Surg:胃腺癌手术后静脉血栓栓塞的预防

研究认为,胃腺癌术后仅进行单纯的间歇气压治疗,对预防静脉血栓栓塞的效果劣于气压联合肝素治疗,但肝素治疗导致患者出血风险增加。未来术后VTE高风险患者的识别将成为研究的重点之一